<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257048</url>
  </required_header>
  <id_info>
    <org_study_id>D6256M00046</org_study_id>
    <secondary_id>2010-023751</secondary_id>
    <nct_id>NCT01257048</nct_id>
  </id_info>
  <brief_title>Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler</brief_title>
  <official_title>An Open, Randomised, Parallel Group Multi-centre, Methodology Study, Evaluating the Sensitivity of Oxygen-Enhanced Magnetic Resonance Imaging (OE-MRI) in Detecting and Comparing Response to 8 Weeks Treatment With Budesonide/Formoterol Turbuhaler® (320/9 µg Bid) and Formoterol Turbuhaler® (9 µg Bid) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the sensitivity of a new oxygen enhanced
      magnetic resonance imaging (OE-MRI) method in detecting changes in the lungs of patients with
      moderate to severe chronic obstructive pulmonary disease (COPD) following treatment with
      either Oxis Turbuhaler or Symbicort Turbuhaler.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygen enhanced MRI V4</measure>
    <time_frame>Visit 4</time_frame>
    <description>Oxygen enhanced magnetic resonance imaging (OE-MRI) parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen enhanced MRI V5</measure>
    <time_frame>Visit 5</time_frame>
    <description>Oxygen enhanced MRI parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen enhanced MRI V7</measure>
    <time_frame>Visit 7</time_frame>
    <description>Oxygen enhanced MRI parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transferability of OE-MRI technique</measure>
    <time_frame>10 months</time_frame>
    <description>Transferability of OE-MRI technique to a second centre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OE-MRI variables</measure>
    <time_frame>patients will fill in a patient diary at home between visit 2 and 7</time_frame>
    <description>Relationship with OE-MRI variables and change in lung function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impulse oscillometry parameters V2</measure>
    <time_frame>Visit 2</time_frame>
    <description>Impulse oscillometry parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impulse oscillometry parameters V4</measure>
    <time_frame>Visit 4</time_frame>
    <description>Impulse oscillometry parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impulse oscillometry parameters V5</measure>
    <time_frame>Visit 5</time_frame>
    <description>Impulse oscillometry parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impulse oscillometry parameters V7</measure>
    <time_frame>Visit 7</time_frame>
    <description>Impulse oscillometry parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>COPD Method Evaluation</condition>
  <condition>Chronic Obstructive Pulmonary Disease Method Evaluation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single Dose evaluation placebo (V5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single Dose evaluation formoterol (V5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Turbuhaler</intervention_name>
    <description>9 microgram on visit 5 single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/Formoterol Turbuhaler</intervention_name>
    <description>320/9 microgram twice daily during 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Turbuhaler</intervention_name>
    <description>9 microgram twice daily during 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 40 years

          -  Male and female

          -  Clinical diagnosis of moderate to severe COPD according GOLD guidelines

          -  Current or ex smoker with a smoking history equivalent to at least 20 cigarettes
             smoked per day for 10 years

          -  A Modified Medical Research Council (MMRC) dyspnoea scale score of ≥2.

          -  FEV1/FVC &lt; 0.7 (post-bronchodilator)

          -  FEV1 &gt; 40 % PN and &lt; 70 % PN (post-bronchodilator)

        Clinical Study Protocol Local Amendment affects UK:

        - FEV1 &gt; 30 % PN and &lt; 80 % PN (post-bronchodilator)

        Exclusion Criteria:

          -  Current diagnosis of asthma according to GINA guidelines

          -  Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not
             using acceptable contraceptive measures as judged by the investigator

          -  Significant upper or lower respiratory tract infection not fully recovered in the 4
             weeks prior to visit 1

          -  Participation in or scheduled for an intensive COPD rehabilitation program

          -  Claustrophobia, pacemaker, clips within the brain, previous brain or heart surgery,
             history of metal in the eye or other MRI contraindication such as obesity or inability
             to stay in the supine position for 60 minutes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>August 31, 2012</last_update_submitted>
  <last_update_submitted_qc>August 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxygen enhanced magnetic resonance imaging</keyword>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>method evaluation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

